BCNU. controlled release system

So far, polyanhydrides have only been approved by the FDA as a drug dehvery system commercially produced by Guilford. Chemotherapeutic agent BCNU (carmustine) loaded in poly(CPP-SA) 20 80 wafer (Gliadel ) was used for treating brain tumors [161,194,195], More applications in controlled release include eye disorder, local anesthetics, and anticoagulants [194], Further biocompatibility analyses need to be conducted for the use of polyanhydrides in other tissue engineering applications. 

Introduction Implantable Controlled Delivery Systems for Chemotherapy Drug Transport after Release from the Implant Application of Diffusion-Elimination Models to Intracranial BCNU Delivery Systems Limitations and Extensions of the Diffusion-Elimination Model New Approaches to Drug Delivery Suggested by Modeling Conclusion References... 

Figure 6 In vitro and in vivo performance of an anticancer drug-loaded microchip delivery system (A) In vitro release of BCNU into phosphate buffer pH 7.2. The reservoirs contained either pure BCNU or binary BCNU PEG blends. The dashed lines indicate the time points of device activation (opening 50% of the reservoirs). (B) Evolution of the tumor size in rat flanks upon SC implantation of BCNU PEG-loaded microchips, containing 0.67, 1.2, or 2.0 mg drug and being activated 11 and 16 days post tumor implantation (50% of the reservoirs being opened at each time), or upon SC injection of die same amounts of BCNU and PEG, or upon SC implantation of a microchip containing 2 mg BCNU, but which was not activated. For reasons of comparison, also a nontreated control group is included. Source From Ref. 49.

---